News

Cathvision completes new investment round of a total 13M euro

Cathvision

26. maj, 2020

CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platfom for cardiac electrophysiology procedures, has completed an investment round of a total 13M euro. Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.

“We are excited to finalize the testing needed for FDA clearance and CE marking, and we expect physicians to acquire clinical data from our system later this year” says CEO Mads Emil Matthiesen. “Our organization has grown rapidly with recent addition of a dedicated software team that allows us to continue to focus on enabling the EP cardiologists to succeed in cardiac ablation for a number of different cardiac arrythmias”.

“This oversubscribed and significant financing round took place in a challenging funding environment for medtech companies and is a clear testimony to the progress we have made over the years in honing our unique technology position in cardiac ablation” says CFO Rune Ørndrup.

We are excited to finalize the testing needed for FDA clearance and CE marking, and we expect physicians to acquire clinical data from our system later this year"

“CathVision is relentlessly delivering on its strategic goal set as the company continues to evolve from a small start-up company to an established cardiology innovator with a strong management team, inhouse product development, clinical operations, and commercialization, We are thankful for the investor confidence shown us in this round” says Chairman Søren Thestrup-Nielsen.

Vaekstfonden invested in Cathvision already in 2017 and participates in the new round as well:

“CathVision has a strong product and works in one of the fastest growing segments of medical technology. Furthermore, CathVision has worked patiently and persistently with its technology for a number of years, and we have been following and continually invested in the company. We strongly believe that Cathvision can become an important player within the industry and that is the reason why we participate in this round,” says Tonni Bülow-Nielsen, Managing Partner in Vaekstfonden’s department of direct investments VF Venture.

Seneste nyheder

Ung gruppe af kolleger
24-06-2020
News

Danish tech company completes first investment round: Will open the “black box” of sales call

The Danish tech company Capturi completes its first investment round of a total €11.6M Euro. Capturi has developed a technology that can identify and categorize the good sales arguments in customer conversations, thus opening up a new world of knowledge about conversation techniques that for many companies has so far been a black box. Now the company is ready to go in the market for customers, and together with Vaekstfonden, employees and a number of private investors have additionally joined the investment.

Vækstfonden
23-06-2020
NEWS

DOES YOUR START-UP NEED A HELPING HAND?

Today we’re launching ‘A Helping Hand’ together with a group of Danish venture investors and industry experts. What is the aim? To help Nordic start-ups adapt to the new normal.

OBI Medical
28-05-2020
News

The global leader in pharmaceutical products and diagnostic tests, Roche, acquires the Danish company OBI Medical ApS

The Swiss company, Roche, has acquired the Danish company OBI Medical in March 2020. Roche is a global leader in pharmaceutical products and diagnostic tests, therefore they saw a potential in the Danish company focusing on developing disruptive blood gas testing technology. OBI Medical has developed a pioneering v-TAC technology that allows for an easier and simpler way to test patients’ blood gas. Today, it is called the Roche v-TAC digital solution and can not only be used to help testing blood gas, but also be a tool to help efficiency in the times of COVID-19 to simplify the monitoring of patients.